EyeGate Pharma, the leader in ocular drug delivery, and a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for its lead clinical compound, EGP-437 (dexamethasone phosphate), delivered via the EyeGate II Iontophoretic Delivery System for the treatment of corneal graft rejection.
The details can be read here.
No comments:
Post a Comment